Biopharma Evumed to Create 30 New Jobs in Cork

Why It Matters

The announcement highlights Ireland’s continued draw for biopharma investment, boosting high‑skill employment and strengthening Europe’s drug‑supply network. It also cements Cork’s status as a strategic location for pharmaceutical R&D and manufacturing.

Key Takeaways

• Evumed to add 30 jobs across quality, regulatory, supply chain, finance
• Multimillion‑euro investment equals about $5.5 million
• Cork Airport Business Park hosts Evumed alongside Amazon, IBM, GSK
• Cork's pharma cluster attracts global firms, boosting regional talent pipeline

Pulse Analysis

Evumed’s decision to locate its European headquarters in Cork reflects a calculated move toward a region renowned for pharmaceutical manufacturing excellence. The Cork Airport Business Park offers unparalleled global connectivity, modern infrastructure, and proximity to a dense network of life‑science companies. By anchoring its operations there, Evumed can streamline regulatory pathways, secure supply‑chain resilience, and tap into a talent pool already versed in generic, branded, and biologic drug development, accelerating its mission to deliver affordable medicines across Europe.

The Evumed expansion arrives amid a broader wave of high‑tech and biopharma investments in the city. Recent announcements from MongoDB—a $80 million infusion creating 200 jobs—and Qumulo’s new European R&D hub illustrate Cork’s magnetic pull for firms seeking favorable tax regimes, skilled graduates, and a collaborative ecosystem. Irish government incentives, such as the Knowledge Development Box and R&D tax credits, further sweeten the proposition, encouraging multinational players to embed themselves in the region’s innovation corridor.

For the local workforce, the 30 new roles represent more than just headline numbers; they signal a deepening of expertise in quality assurance, regulatory affairs, and supply‑chain management—critical functions that underpin the continent’s drug‑supply stability. As Europe grapples with drug shortages and rising healthcare costs, the presence of a dedicated biopharma hub in Cork enhances the continent’s capacity to produce high‑quality, cost‑effective medicines. In the long term, this bolsters Ireland’s reputation as a cornerstone of the European pharmaceutical landscape, attracting further capital and fostering a virtuous cycle of job creation and industry growth.